AMGEN: "A Phase 1b/3, Multicenter, Open-label Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of Unresected,Stage IIIB to IVM1c Melanoma (MASTERKEY-265)", INTERNET CITATION, 22 June 2015 (2015-06-22), XP002762393, Retrieved from the Internet: URL:https://clinicaltrials.gov/archive/NCT 02263508/2015_06_22 [retrieved on 2016-09-28] (B1)

I Puzanov ET AL: "151884-156", ASCO, Meeting Library: "Survival, safety, and response patterns in a phase 1b multicenter trial of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB-IV melanoma"., 1 January 2015 (2015-01-01), pages 1-2, XP055344664, Retrieved from the Internet: URL:http://meetinglibrary.asco.org/print/2 001901 [retrieved on 2017-02-10] (B1)

WO-A1-2015/077624 (B1)

Robert H Andtbacka: "The role of talimogene laherparepvec (T-VEC) in the age of checkpoint inhibitors", Clinical advances in hematology & oncology : H&O, 1 August 2016 (2016-08-01), August 2016 (2016-08), page 576, XP055344660, United States Retrieved from the Internet: URL:http://www.hematologyandoncology.net/f iles/2016/08/ho0816Melanoma-1.pdf [retrieved on 2017-02-10] (B1)

TUULI RANKI ET AL: "Phase I study with ONCOS-102 for the treatment of solid tumors - an evaluation of clinical response and exploratory analyses of immune markers", JOURNAL FOR IMMUNOTHERAPY OF CANCER, vol. 4, no. 1, 15 March 2016 (2016-03-15), XP055344677, DOI: 10.1186/s40425-016-0121-5 (B1)

PETROS FESSAS ET AL: "A molecular and preclinical comparison of the PD-1-targeted T-cell checkpoint inhibitors nivolumab and pembrolizumab", SEMINARS IN ONCOLOGY, vol. 44, no. 2, 1 April 2017 (2017-04-01), pages 136-140, XP055557883, US ISSN: 0093-7754, DOI: 10.1053/j.seminoncol.2017.06.002 (B1)